Ongoing trials: What should we expect after ALLHAT?
Tóm tắt
The publication of the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results, when used in conjunction with a new meta-analysis, provides hypertension research with a watershed. Data demonstrate clearly that lowering blood pressure is the most important aspect of hypertension management, and that all agents are similarly effective. There is little sustainable evidence for pressure-independent advantages for any class of drug at this time. Therefore, by combining these findings with additional information on target levels of blood pressure and safety, plus the use of aspirin and statins, we can formulate health care policies that attack hypertension in a holistic risk-based way. The future will focus on gaining extra benefit for patients by testing the efficacy and superiority of drug combinations using novel agents that favorably influence intermediate markers such as arterial stiffness, and arresting the ever-increasing burden of cognitive impairment and dementia.
Tài liệu tham khảo
Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 1985, 291:97–104.
Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1979, 213:1143–1152.
SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255–3264.
Dahlöf B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension. (STOP — Hypertension). Lancet 1991, 338:1281–1285.
MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405–412.
Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762.
The Heart Outcomes Prevention Evaluation Study Investigators:Effects on an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.The addition of the ACE inhibitor ramipril to established treatment regimens in high-risk patients produced additional protection, which could not be ascribed to a fall in blood pressure.
Svenson P, de Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood results: a HOPE substudy. Hypertension 2001, 38:e28-e32.
The Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminaria or Proteinuria, Cardiovascular Events and Ramipril (DIABHYCAR) Study: design, organisation and patient recruitment. Control Clin Trial 2000, 21:383–396.
Lindholm LH, Ibsen H, Dahlöf B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.In this study, losartan significantly reduced relative risk in all patients and was even better in a subgroup of diabetics.
Staessen JA, Wang Ji-Guang, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315.
Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994, 50:272–298.
Staessen J, Wang J-G, Birkenhager WH: Outcome beyond blood pressure control? Eur Heart J 2003, 24:504–514.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomised to angiotensin-coverting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.Chlorthalidone was found to be superior to doxazosin. In terms of secondary outcomes, chlorthalidone was superior in preventing heart failure, and was better than lisinopril in preventing stroke, combined cardiovascular disease, and heart failure.